WCN 2021 | Learnings from laquinimod in MS
Giancarlo Comi
• 28 Sep 2021
Giancarlo Comi, MD, Vita-Salute San Raffaele University, Milan, Italy, shares some of the learnings from the clinical trials of laquinimod for the treatment of multiple sclerosis. Although the results were not satisfactory, the studies provided valuable insights. Prof. Comi highlights that interventions during the more advanced states of neurodegenerative disorders are highly challenging. Therefore, interventions should be applied early in the disease course. This interview took place during the XXV World Congress of Neurology.
Disclosures
Prof. Comi has received consulting and speaking fees from Novartis, Sanofi Genzyme, Genzyme Corporation, Merck KGgA, Merck Serono SpA, Celgene Group, F. Hoffman-La Roche, Almirall SpA, Janssen.
